Results 1 to 10 of about 2,433 (185)

Genetic Determinants of Hematopoietic Toxicity Risk in Thai Pediatric Patients Undergoing 6‐Mercaptopurine Treatment [PDF]

Clinical and Translational Science
The nucleoside diphosphate‐linked moiety X‐type motif 15 (NUDT15) has been identified as a key genetic determinant of 6‐mercaptopurine (6‐MP)‐induced hematopoietic toxicity in populations with a high frequency of NUDT15 variants but a low frequency of ...
Kanyarat Khaeso, Su‐on Chainansamit, Pitchayanan Kuwatjanakul, Patcharee Komvilaisak, Nontaya Nakkam, Kunanya Suwannaying, Suda Vannaprasaht, Areerat Dornsena, Wichittra Tassaneeyakul   +8 more
doaj   +3 more sources

Pharmacogenomics of Thiopurine Drugs: A Bench‐To‐Bedside Success Story in Thailand [PDF]

Clinical and Translational Science
Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases ...
Mohitosh Biswas, Shobana John, Murshadul Alam Murad, Chonlaphat Sukasem   +3 more
doaj   +3 more sources

Higher prevalence of NUDT15 rs116855232 compared to TPMT rs1142345 in a Chinese cohort and its implications for thiopurine therapy [PDF]

Frontiers in Pharmacology
BackgroundThiopurine drugs are widely used as immunosuppressants and chemotherapeutic agents in clinical practice, but their adverse effects significantly limit their clinical application. TPMT c.719A>G (rs1142345) and NUDT15 c.415C>T (rs116855232)
Chenyu Zhao, Chenyu Zhao, Hui Huang
doaj   +2 more sources

Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss [PDF]

MedComm
Somatic retinoblastoma 1 (RB1) loss is prevalent across different cancer types and is enriched in treatment‐refractory tumors, such as castration‐resistant prostate cancer (CRPC) and small‐cell lung cancer, but cannot be considered as a direct druggable ...
Tao Zhou, Huayun Yan, Dandan Yin, Yun Deng, Huancheng Fu, Zichen Zhao, Shuang Li, Xiaoxi Lu, Yiqi Deng, Hai‐Ning Chen, Wei‐Han Zhang, Yunying Shi, Yangjuan Bai, Bei Cai, Lanlan Wang, Zhaoqian Liu, Wei Zhang, Lili Jiang, Yang Shu, Bo Liu, Yan Zhang, Heng Xu   +21 more
doaj   +2 more sources

NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy [PDF]

Medical Sciences
The management of acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, critically relies on thiopurine therapy, such as 6-mercaptopurine (6-MP), during the maintenance phase. However, significant inter-individual response variety and
Isfahan Shah Lubis, Kusnandar Anggadiredja, Aluicia Anita Artarini, Nur Melani Sari, Nur Suryawan, Zulfan Zazuli   +5 more
doaj   +2 more sources

Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in indian pediatric acute lymphoblastic leukemia patients [PDF]

Frontiers in Pharmacology
BackgroundThiopurines such as 6-mercaptopurine (6-MP) are central to maintenance therapy for pediatric acute lymphoblastic leukemia (ALL), yet their narrow therapeutic index frequently causes dose-limiting myelosuppression in genetically susceptible ...
Gratial Theres Joseph, Gratial Theres Joseph, Sandeep Kumar Swain, Tejas Somwanshi, Aarishi Singh, Manpreet Kaur, Raj Kamal, Himanshu Dhanda, Himanshu Dhanda, Prashant Kumar, Upasana Kaushik, Baseer Noor, Baseer Noor, Saurabh Sharma, Pranay Tanwar, Sufian Zaheer, Sumita Chaudhry, Prashant Prabhakar, Amitabh Singh, Bhavika Rishi, Aroonima Misra   +20 more
doaj   +2 more sources

Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource. [PDF]

Aliment Pharmacol Ther
BackgroundThe clinical utility and cost-effectiveness of pre-thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.AimsTo report the prevalence, penetrance, expressivity, and pathogenicity of NUDT15 variant allele ...
Roberts C, Peters J, Sazonvos A, Goodman N, Sharip M, Smith R, Bishara M, Bewshea C, Lin S, Chanchlani N, Hodges P, Badrulhisham F, Saifuddin A, Carlson S, Centritto A, Marley A, Saad M, Sethi-Aora K, White L, Abdelmeguid A, Pele L, Sebastian S, Selinger C, Irving P, Fachal L, Walker G, Palmer R, Kennedy N, Houghton J, Doona M, Lamb C, Hyde C, Parkes M, Goodhand J, Ahmad T.   +34 more
europepmc   +3 more sources

Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial. [PDF]

JMIR Res Protoc
Background: Valganciclovir (VGCV) is the first-line drug for preemptive therapy of cytomegalovirus (CMV) infections. However, even when administered at the dose specified in the package insert, there is significant interindividual variability in the ...
Tamura N, Itohara K, Ueda Y, Kitahiro Y, Yamamoto K, Omura T, Sakane T, Saegusa J, Yano I.   +8 more
europepmc   +2 more sources

Clinical impact of pharmacogenetic risk variants in a large chinese cohort. [PDF]

Nat Commun
Incorporating pharmacogenetics into clinical practice promises to improve therapeutic outcomes by optimizing drug selection and dosage based on genetic factors affecting drug response.
Wei CY, Wen MS, Cheng CK, Sheen YJ, Yao TC, Lee SL, Wu JY, Tsai MF, Li LH, Chen CH, Fann CS, Yang HC, Huang YT, Chen HH, Liu YM, Yeh EC, Peng YC, Wang SJ, Chen SP, Tsai MT, Huo TI, Su CW, Tarng DC, Huang CC, Fuh JL, Lan KH, Liu YT, Lu CL, Lee YC, Huang YH, Li CP, Wang YF, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chang JH, Huang CY, Chan L, Lin YW, Hsiao BY, Hu CJ, Lin YK, Lin YF, Chang TC, Wu DC, Kan JY, Hsu CY, Chen SC, Li CC, Huang CF, Sheu CC, Yang LJ, Chen CH, Chen KM, Chang SM, Liou MS, Wang SP, Lin KT, Chuang HP, Chen YJ, Sin J, Chen YT, Chang CC, Kuo CF, Lin JC, Kuo HC, Chan TM, Lee CW, Lai JH, Luo SF, Cheng HT, Lin LY, Chang LC, Tsai CT, Kao HL, Yu JJ, Jeng JS, Chiu MC, Hong TC, Yang SF, Lu HJ, Su SC, Chu P, Li PF, Tsai CL, Tsai CK, Tang SE, Lin CM, Wu YF, Huang CY, Ling SZ, Chang CC, Lin TK, Hsiao SM, Chang CH, Chen CD, Ma GC, Chang TY, Hwang JJ, Lu CL, Kao KJ, Hung CF, Chen SS, Chen PY, Tsui K, Chen YT, Chen CH, Chien CC, Chiang HS, Chiu YL, Chen HC, Kwok PY.   +123 more
europepmc   +3 more sources

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease [PDF]

, 2019
Importance: Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry.

core   +12 more sources